Search NASA⌕ Search

SEARCH · Search NASA

Results for “lutetium”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

50 records · Page 3
All sourcesNASA NTRSDOE OSTI
DOE OSTI2023

Beam Test Results of the RADiCAL—A Radiation Hard Innovative EM Calorimeter

High-performance calorimetry conducted at future hadron colliders, such as the FCC-hh, poses a significant challenge for applying current detector technologies due to unprecedented beam luminosities and radiation fields. Solutions include developing scintillators that are capable of separating events at the sub-fifty picosecond level while also maintaining performance after extreme and constant neutron and ionizing radiation exposure. The radiation-hard innovative calorimeter (RADiCAL) is an approach that incorporates radiation tolerant materials in a sampling “shashlik”-style calorimeter configuration, using quartz capillaries filled with organic liquid or polymer-based wavelength shifters embedded in layers of tungsten plates and lutetium-yttrium oxyorthosilicate (LYSO) crystals. Here, this novel design intends to address the priority research directions (PRD) for calorimetry listed in the DOE basic research needs (BRN) workshop for high energy physics (HEP) instrumentation. Here we report preliminary results from an experimental run at the Fermilab Test Beam Facility (FTBF) in June 2022. These tests demonstrate that the RADiCAL concept is capable of ¡50 ps timing resolution.

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗
DOE OSTI2025

Yb:Lu 2 O 3 single-crystal fiber: spectroscopy, amplification, and lasing

For the first time, to our knowledge, a lutetium oxide (Lu 2 O 3 ) single-crystal fiber (SCF) laser is demonstrated. The laser heated pedestal growth (LHPG) technique was used to pull Yb-doped Lu 2 O 3 SCFs between 10 and 50 mm long and with diameters between 150 and 225 μm. Spectroscopic properties are first reported in detail, as the two-site nature of the host demands careful attention. Short 10 mm long, unclad fibers were used as amplifier media in a single pass copropagating configuration. Then, a 50 mm long 0.1%Yb:Lu 2 O 3 SCF with a 180 μm diameter was configured to lase by butt-coupling mirrors on the ends and pumping at 976 nm. Lasing occurred at the 1033 nm peak of Yb, and a maximum output of around 300 mW is reported. Finally, the results indicate there is no, at least obvious, fundamental reason that should deter future interest in Lu 2 O 3 as a SCF platform, which has been considered to have high potential for power scaling based on its beneficial intrinsic properties.

47 OTHER INSTRUMENTATION↗
DOE OSTI2025

Production and purification of research scale 161 Tb using cation-exchange semi-preparative HPLC for radiopharmaceutical applications

Terbium-161 ( 161 Tb) is emerging as a promising radionuclide for cancer therapy due to its favorable nuclear properties that are similar to clinically established lutetium-177 ( 177 Lu) along with its therapeutic edge arising from the higher number of Auger and conversion electrons per decay. These low energy electrons result in higher cytotoxicity within a short range of the decaying nuclei to enhance therapeutic efficacy. Despite these promising characteristics, a significant challenge remains in the lack of a domestic 161 Tb supply in the United States, which poses an obstacle to the advancement of 161 Tb-based radiopharmaceutical research and development. Here, this study developed a reliable cation-exchange high-performance liquid chromatography-based method for purification of reactor-produced 161 Tb at quantities suitable to support research and preclinical studies. The purified 161 Tb product showed high radionuclidic purity with excellent radiochemical purity, and the successful labeling studies with the DOTA chelator and DOTA-TATE peptide demonstrated the effective incorporation of the purified 161 Tb into radiopharmaceuticals designed for targeted cancer therapy.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2020

Materials Data on Ba2LuSbO6 by Materials Project

Lu(BaO3)2Sb is alpha Rhenium trioxide-derived structured and crystallizes in the tetragonal I4/mmm space group. The structure is three-dimensional and consists of two antimony molecules, two lutetium molecules, and one BaO3 framework. In the BaO3 framework, Ba2+ is bonded to six O2- atoms to form corner-sharing BaO6 octahedra. The corner-sharing octahedral tilt angles are 0°. There are four shorter (2.35 Å) and two longer (2.36 Å) Ba–O bond lengths. There are four inequivalent O2- sites. In the first O2- site, O2- is bonded in a linear geometry to two equivalent Ba2+ atoms. In the second O2- site, O2- is bonded in a linear geometry to two equivalent Ba2+ atoms. In the third O2- site, O2- is bonded in a linear geometry to two equivalent Ba2+ atoms. In the fourth O2- site, O2- is bonded in a linear geometry to two equivalent Ba2+ atoms. Both O–Ba bond lengths are 2.35 Å.

36 MATERIALS SCIENCE↗
DOE OSTI2020

First observation of the production of three massive vector bosons and search for long-lived particles using delayed photons in pp collisions at $\sqrt{s}=13\text{ TeV}$

This thesis presents the first observation of the production of three massive vector bosons (VVV with V = W, Z) in proton-proton collisions at the LHC at $\sqrt{s}=13\text{ TeV}$. The search was performed in final states with two same-sign charged leptons (electrons or muons) plus one or two jets, and three, four, five, or six leptons from WWW, WWZ, WZZ and ZZZ decays, with a data sample corresponding to an integrated luminosity of 137 fb -1 collected by the CMS experiment during 2016-2018. The observed (expected) significance of the combined VVV production is 5.7 (5.9) standard deviations, and the production cross section is measured to be 1010$^{+210}_{-200}$(stat) $^{+150}_{-120}$(syst) fb, corresponding to a signal strength of 1.02$^{+0.26}_{-0.23}$. We also found evidence for WWW and for WWZ production, with observed significances of 3.3 and 3.4 standard deviations, respectively. The measured production cross sections for individual VVV processes are also reported. The establishment of VVV production opens a new program of many standard model studies (such as gauge-gauge and Higgs-gauge couplings), and provides a new tool for many new physics searches (such as anomalous gauge coupling searches, new resonance searches). This thesis also reports a search for long-lived supersymmetry particles decaying to photons in proton-proton collisions at the LHC at $\sqrt{s} = 13 TeV$, with a data sample corresponding to an integrated luminosity of 77.4 fb -1 collected by CMS during 2016-2017. Results are interpreted with a gauge-mediated supersymmetry breaking model, where the long-lived particle is a neutralino and the lightest supersymmetry particle is a gravitino. For neutralino proper decay lengths of 0.1, 1, 10, and 100 m, masses up to 320, 525, 360, and 215 GeV are excluded at 95% confidence level, respectively. This result extends the limits from previous searches by one order of magnitude for the neutralino proper decay length and up to 100 GeV more for the neutralino mass. Motivated by the need for precision timing measurements for long-lived particle searches, as well as for improvements in general object reconstruction performance, the timing performance of two types of sensors are studied in this thesis: one with a Cerium doped Lutetium Yttrium Orthosilicate (LYSO:Ce) crystal as the scintillator and a silicon photomultiplier (SiPM) as the photodetector, another with a Cadmium-Telluride sensor as the active material for a sampling calorimeter. Both setups have been demonstrated with test beams to be able to provide timing measurements of particles with a resolution below 30 ps.

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗
DOE OSTI2025

Microtron Data Log

The Microtron at Los Alamos National Laboratory (LANL) is a versatile electron accelerator originally designed for medical therapy. Since 2001, it has been used for non-destructive radiographic imaging and research and development applications. Operating at four different energy levels—6, 10, 15, and 20 MeV—the Microtron produces dose rates of approximately 780, 1800, 2700, and 2800 R/min at a distance of one meter from the source, respectively. This high-energy X-ray source enables detailed internal examination of dense and thick objects without causing damage, making it invaluable for various scientific and industrial applications. For instance, LANL’s Microtron has been utilized to study the performance of large-panel cerium-doped lutetium yttrium silicon oxide (LYSO) scintillators, which are essential components in advanced imaging systems.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2021

Production, Purification, and Applications of a Potential Theranostic Pair: Cobalt-55 and Cobalt-58m

The emerging success of [68Ga/177Lu]Ga/Lu-DOTATATE as a theranostic pair has spurred interest in other isotopes as potential theranostic combinations. Here, we review cobalt-55 and cobalt-58m as a potential theranostic pair. Radionuclidically pure cobalt-55 and cobalt-58m have been produced on small cyclotrons with high molar activity. In vitro, DOTATOC labeled with cobalt has shown greater affinity for SSTR2 than DOTATOC labeled with gallium and yttrium. Similarly, [58mCo]Co-DOTATATE has shown improved cell-killing capabilities as compared to DOTATATE labeled with either indium-111 or lutetium-177. Finally, PET imaging with an isotope such as cobalt-55 allows for image acquisition at much later timepoints than gallium, allowing for an increased degree of biological clearance of non-bound radiotracer. We discuss the accelerator targetry and radiochemistry used to produce cobalt-55,58m, emphasizing the implications of these techniques to downstream radiotracers being developed for imaging and therapy.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2023

Design of Monolithic Bi-Layer High-Z PAL-Si Hard X-ray CMOS Image Sensors for Quantum Efficiency Enhancement

This article experimentally investigates the inception of an innovative hard X-ray photon energy attenuation layer (PAL) to advance high-energy X-ray detection (20–50 keV). A bi-layer design with a thin film high-Z PAL on the top and Si image sensor on the bottom has previously demon-strated quantum yield enhancement via computational methods by the principle of photon energy down conversion (PEDC), where high-energy X-ray photon energies are attenuated via inelastic scattering down to ≤10 keV, which is suitable for efficient photoelectric absorption by Si. Quantum yield enhancement has been experimentally confirmed via a preliminary demonstration using PAL-integrated Si-based CMOS image sensors (Si CIS). Furthermore, substituting the high-Z PAL with a lower-Z material—Sn—and alternatively coupling it with a conventional scintillator ma-terial—Lutetium-yttrium oxyorthosilicate (LYSO)—have been compared to demonstrate the most prominent efficacy of monolithic integration of high-Z PAL on Si CIS to detect hard X-rays, paving the way for next-generation high-energy X-ray detection methods.

47 OTHER INSTRUMENTATION↗
DOE OSTI2022

The Synthesis and Structure of a Scandium Nitrate Hydroxy-Bridged Dimeric Complex Supported by Bipyridyl Ligands

The current discussion on whether scandium, yttrium and lanthanum should represent Group 3 in the Periodic Table or whether lutetium should replace lanthanum in the group has prompted us to further explore the structural chemistry of the Group 3 elements and compare the coordination numbers and coordination geometries adopted. The steric and electronic properties of the coordinated ligands have a major influence on the structures adopted. We report the synthesis and crystal structure determination of an unusual dinuclear scandium complex [(bipy)(NO 3 ) 2 Sc(µ-OH) 2 Sc(NO 3 ) 2 (bipy)] obtained by the reaction of hydrated scandium nitrate with 2,2'-bipyridyl (bipy) in either ethanol or nitromethane. The crystal structure of the complex shows that the scandium centers are eight coordinate, and the structure obtained contrasts with related complexes found in the lanthanide series [Ln(bipy) 2 (NO 3 ) 3 ] and [Ln(phen) 2 (NO 3 ) 3 ] (phen = phenanthroline) and in [M(terpy)(NO 3 ) 3 ] (M = Sc, Er–Lu), where these complexes are all mononuclear.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
DOE OSTI2026

Isotope harvesting from a NSCL beam blocker: Isolation of 173,174 lu

A decommissioned beam blocker from the National Superconducting Cyclotron Laboratory was processed for recovery of long-lived Lu radioisotopes at Lawrence Livermore National Laboratory. The beam blocker was a W alloy that had built up considerable levels of activation from high energy particle irradiation over the course of 20 years. The isolation of 173,174 Lu from the bulk material required a complex chemical separation scheme due to the large mass and the wide variety of elements present. The final yield of 173,174 Lu was 76.7 ± 4.8% with an extremely high radiopurity and chemical purity. The reduction in W mass from the initial material to the final sample was 8 × 10 10 . In conclusion, the results show great promise for extracting large quantities of Lu radioisotopes from these types of W beam blockers at the Facility for Rare Isotope Beams, which will be irradiated at levels significantly higher than the beam blocker investigated here.

and nuclear chemistry↗
DOE OSTI2021

Current Status of Radiopharmaceutical Therapy

In radiopharmaceutical therapy (RPT), a radionuclide is systemically or locally delivered with the goal of targeting and delivering radiation to cancer cells while minimizing radiation exposure to untargeted cells. Examples of current RPTs include thyroid ablation with the administration of {sup 131}I, treatment of liver cancer with {sup 90}Y microspheres, the treatment of bony metastases with {sup 223}Ra, and the treatment of neuroendocrine tumors with {sup 177}Lu-DOTATATE. New RPTs are being developed where radionuclides are incorporated into systemic targeted therapies. To assure that RPT is appropriately implemented, advances in targeting need to be matched with advances in quantitative imaging and dosimetry methods. Currently, radiopharmaceutical therapy is administered by intravenous or locoregional injection, and the treatment planning has typically been implemented like chemotherapy, where the activity administered is either fixed or based on a patient’s body weight or body surface area. RPT pharmacokinetics are measurable by quantitative imaging and are known to vary across patients, both in tumors and normal tissues. Therefore, fixed or weight-based activity prescriptions are not currently optimized to deliver a cytotoxic dose to targets while remaining within the tolerance dose of organs at risk. Methods that provide dose estimates to individual patients rather than to reference geometries are needed to assess and adjust the injected RPT dose. Accurate doses to targets and organs at risk will benefit the individual patients and decrease uncertainties in clinical trials. Imaging can be used to measure activity distribution in vivo, and this information can be used to determine patient-specific treatment plans where the dose to the targets and organs at risk can be calculated. The development and adoption of imaging-based dosimetry methods is particularly beneficial in early clinical trials. In this work we discuss dosimetric accuracy needs in modern radiation oncology, uncertainties in the dosimetry in RPT, and best approaches for imaging and dosimetry of internal radionuclide therapy.

62 RADIOLOGY AND NUCLEAR MEDICINE↗
DOE OSTI2020

Evaluating 225 Ac and 177 Lu Radioimmunoconjugates against Antibody–Drug Conjugates for Small-Cell Lung Cancer

Interest in the use of 225 Ac for targeted alpha therapies has increased dramatically over the past few years, resulting in a multitude of new isotope production and translational research efforts. However, 225 Ac radioimmunoconjugate (RIC) research is still in its infancy, with most prior experience in hematologic malignancies and only one reported preclinical solid tumor study using 225 Ac RICs. In an effort to compare 225 Ac RICs to other current antibody conjugates, a variety of RICs are tested against intractable small-cell lung cancer (SCLC). Here we directly compare, in vitro and in vivo , two promising candidates of each α or β - category, 225 Ac and 177 Lu, versus pyrrolobenzodiazepine (PBD) nonradioactive benchmarks. The monoclonal antibody constructs are targeted to either delta like 3 protein (DLL3), a recently discovered SCLC target, or CD46 as a positive control. An immunocompromised maximum tolerated dose assay is performed on NOD SCID mice, along with tumor efficacy proof-of-concept studies in vivo . We overview the conjugation techniques required to create serum-stable RICs and characterize and compare in vitro cell killing with RICs conjugated to nonspecific antibodies (huIgG1) with either native or site-specific thiol loci against tumor antigen DLL3-expressing and nonexpressing cell lines. Using patient-derived xenografts of SCLC onto NOD SCID mice, solid tumor growth was controlled throughout 3 weeks before growth appeared, in comparison to PBD conjugate controls. NOD SCID mice showed lengthened survival using 225 Ac compared to 177 Lu RICs, and PBD dimers showed full tumor suppression with nine out of ten mice. The exploration of RICs on a variety of antibody-antigen systems is necessary to direct efforts in cancer research toward promising candidates. However, the anti-DLL3-RIC system with 225 Ac and 177 Lu appears to be not as effective as the anti-DLL3-PBD counterpart in SCLC therapy with matched antibodies and portrays the challenges in both SCLC therapy as well as the specialized utility of RICs in cancer treatment.

60 APPLIED LIFE SCIENCES↗